Notably, in CRC, the therapeutic effect of anti-TGF-β1 may not replace that of targeting ATP6V0A1 since anti-TGF-β1 treatment only partially weakened the promoting effect of Atp6v0a1 overexpression on MC38 tumor growth. Here, ATP6V0A1 is linked to colorectal carcinoma.